Header Logo

Connection

Kamyar Kalantar-Zadeh M.D. to Clinical Trials, Phase II as Topic

Back to Details
This is a "connection" page, showing publications Kamyar Kalantar-Zadeh M.D. has written about Clinical Trials, Phase II as Topic.
Kamyar Kalantar-Zadeh M.D.
Connection Strength
0.163
Clinical Trials, Phase II as Topic
  1. Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. Atherosclerosis. 2019 11; 290:59-65.
    View in: PubMed
    Score: 0.163
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.